Using flash glucose monitoring as a tool to achieve compensation of carbohydrate metabolism in a patient with type 2 diabetes mellitus

In recent years, significant progress has been made in glucose monitoring technologies, which allow patients with type 2 diabetes mellitus (T2DM) to more accurately monitor glucose levels and respond quickly to changes. The use of new technologies in the treatment of T2DM, including flash monitoring of glycemia (FMG), helps to select the appropriate hypoglycemic therapy for a particular patient, as well as motivate them to lifestyle changes. In the presented clinical case, a patient with T2DM received basic bolus insulin therapy, however, against its background, compensation for carbohydrate metabolism was not achieved. To assess the causes of hyperglycemia, select and optimize hypoglycemic therapy, as well as motivate the patient to treat diabetes, an FMG system was installed for the patient. Against the background of monitoring, the patient began to calculate the dose of ultrashort-acting insulin, taking into account the bread units consumed, changed his diet, which allowed him to reach the target glucose values as soon as possible, after which the ultrashort-acting insulin was discontinued and metformin was added to therapy. Thus, the patient's commitment to therapy and lifestyle changes during FMG helped to achieve compensation for T2DM. This clinical case demonstrates the importance of using modern glucose monitoring technologies, as well as a combination of various treatment methods to achieve target blood glucose levels in patients with T2DM.

1. Sun H, Saeedi P, Karuranga S et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 [published correction appears in Diabetes Res Clin Pract. 2023; 204: 110945]. Diabetes Res Clin Pract. 2022; 183: 109119. doi: 10.1016/j.diabres.2021.109119

2. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016; 19(2): 104–112. doi: 10.14341/DM2004116-17.

3. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007; 28(1): 88–136. doi:10.1093/eurheartj/ehl260.

4. Polonsky WH, Fisher L, Schikman CH et al. A structured self-monitoring of blood glucose approach in type 2 diabetes encourages more frequent, intensive, and effective physician interventions: Results from the STeP study. Diabetes Technol Ther. 2011; 13(8): 797–802. doi: 10.1089/dia.2011.0073.

5. Carlson AL, Mullen DM, Bergenstal RM. Clinical use of continuous glucose monitoring in adults with type 2 diabetes. Diabetes Technol Ther. 2017; 19(S2): S4–11. doi: 10.1089/dia.2017.0024.

6. De Ridder F, den Brinker M, De Block C. The road from intermittently scanned glucose monitoring to hybrid closed-loop systems: Part A. Keys to success: subject profiles, choice of systems, education. Ther Adv Endocrinol Metab. 2019; 10:2 042018819865399. doi: 10.1177/2042018819865399.

7. Haak T, Hanaire H, Ajjan R, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin treated type 2 diabetes: A multicenter, open-label randomized controlled trial. Diabetes Ther. 2017; 8(1): 55–73. doi: 10.1007/s13300-016-0223-6.

8. Haak T, Hanaire H, Ajjan R et al. Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes. Diabetes Ther. 2017; 8(3): 573–86. doi: 10.1007/s13300-017-0255-6.

9. Ajjan RA, Jackson N, Thomson SA. Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial. Diab Vasc Dis Res. 2019; 16(4): 385–95. doi: 10.1177/1479164119827456.

10. Yaron M, Roitman E, Aharon-Hananel G et al. Effect of flash glucose monitoring technology on glycemic control and treatment satisfaction in patients with type 2 diabetes. Diabetes Care. 2019; 42(7): 1178–84. doi: 10.2337/dc18-0166.

11. Kroger J. Fasching, Hanaire H. Three European retrospective real-world chart review studies to determine the effectiveness of flash glucose monitoring on HbA1c in adults with type 2 diabetes. Diabetes Ther. 2020; 11(1): 279–91. doi: 10.1007/s13300-019-00741-9.

12. Wright EE Jr, Kerr MSD, Reyes IJ et al. Use of flash continuous glucose monitoring is associated with a1c reduction in people with type 2 diabetes treated with basal insulin or noninsulin therapy. Diabetes Spectr. 2021; 34(2): 184–89. doi: 10.2337/ds20-0069.

13. Miller E, Brandner L, Wright E. HbA1c reduction after initiation of the FreeStyle Libre® system in type 2 diabetes patients on long-acting insulin or non-insulin therapy. Diabetes. 2020; 69(Suppl_1): 84–LB. doi: 10.2337/db20-84-LB.

14. Bergenstal RM, Kerr MSD, Roberts G, et al. FreeStyle Libre® system use is associated with reduction in inpatient and outpatient emergency acute diabetes events and all-cause hospitalizations in patients with type 2 diabetes. Diabetes. 2020; 69(Suppl_1): 69–OR. doi: 10.2337/db20-69-OR.